Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07855497 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Second-Line Helicobacter Pylori Eradication

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Subjects with persistent H. pylori infection after first-line treatment failure receives either a 14-day PPI-based moxifloxacin triple regimen (esomeprazole, amoxicillin, and moxifloxacin) or a 14-day P-CAB-bismuth-containing moxifloxacin quadruple regimen (tegoprazan, amoxicillin, moxifloxacin, and bismuth).
Trial Details
NCT Number NCT07855497
Lead Sponsor Seoul National University Bundang Hospital
Conditions
(from sponsor)		 HELICOBACTER PYLORI INFECTIONS
Enrollment 141 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov